Agilon Health, Inc.'s (NYSE:AGL) Chief Markets Officer, Benjamin Shaker, has recently made significant transactions in the company's stock, according to a new SEC filing. On March 14, 2024, Shaker acquired 274,455 shares of common stock. This transaction was part of a performance-based award that vested based on the company's revenue and adjusted EBITDA goals over a three-year period.
The shares were granted as performance-based restricted stock units (PSUs) and vested after the company achieved total attainment of 100% of its predetermined goals from January 1, 2021, through December 31, 2023. Upon vesting, these PSUs were settled in shares of common stock.
On the same day, to satisfy tax withholding obligations related to the vested PSUs, Shaker withheld 95,266 shares, valued at a price of $5.23 per share, totaling approximately $498,241. This withholding does not represent a sale of shares but is a common practice for settling tax obligations in connection with the vesting of equity awards.
After these transactions, Benjamin Shaker's direct ownership in Agilon Health, Inc. stands at 258,732 shares, including restricted stock units. The recent filings provide a glimpse into the executive compensation structure at Agilon Health, aligning leadership interests with the company's performance and long-term goals.
InvestingPro Insights
Agilon Health, Inc. (NYSE:AGL), while experiencing significant internal movements with its Chief Markets Officer's recent stock transactions, also presents an interesting picture from an investment standpoint. According to InvestingPro data, AGL has a market capitalization of $2.21 billion and has seen a substantial revenue growth of 80.74% in the last twelve months as of Q4 2023. Despite this growth, the company's gross profit margin remains low at 1.61%, reflecting some of the challenges it faces in terms of profitability.
InvestingPro Tips for AGL highlight a mixed financial outlook. On one hand, the management's aggressive share buyback strategy and the fact that the company holds more cash than debt on its balance sheet could be seen as positive indicators of financial prudence and a potentially strong shareholder yield. On the other hand, analysts do not expect the company to be profitable this year, and the stock has been trading near its 52-week low with a significant price drop over the last year.
For investors considering AGL, these insights suggest a need to weigh the robust revenue growth against the profitability concerns and market sentiment. To explore more in-depth analysis and additional InvestingPro Tips, which can provide a clearer picture of Agilon Health's financial health and market position, visit https://www.investing.com/pro/AGL. For those looking to access a comprehensive suite of investment tools and data, use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. There are 12 more InvestingPro Tips available for AGL, offering a more nuanced understanding of the company's financial and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.